Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 2/2015

01.06.2015 | original report

Lung cancer in Bulgaria ‒ diagnosis, treatment, and factors affecting survival

Bulgarian Single Institution experience in lung cancer treatment

verfasst von: MD, PhD Zhasmina Mihaylova, MD Vera Megdanova, MD Veneta Petrova, MD Dobromira Petkova, MD Albena Fakirova, MD, PhD Mihaela Petrova, MD, PhD Rumen Asenov, MD Iva Kisjova, MD, PhD Milena Encheva, MD Hristo Dinev

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Abstract

Background

In Bulgaria, lung cancer incidence and mortality rates are rising in both men and women. The study aims to present a picture of lung cancer diagnosis and treatment process and to identify factors affecting survival in advanced lung cancer patients (LCP) treated with systemic therapy.

Patients and methods

Data from LCP admitted at the Medical Oncology Department were retrospectively collected from electronic and hard-paper database for a 10-year period (January 2005–2015). The test for frequencies was used to describe parameters. Kaplan–Mayer estimates with two-sided 95 % confidence interval (CI) were calculated for clinical and laboratory prognostic factors in advanced LCP who received medical therapy. Cox-regression model was used for the evaluation of significant prognostic factors’ impact on survival. Statistical analyses were performed using SPSS 9.0 software.

Results

Data from 204 LCP were retrospectively analyzed for a period between January 2005 and January 2015. LCP characteristics were as follows: median age 60.2 years (range 28–78), male/female (M/F) 159/55, Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0–1/> 2 136/63, no comorbidity/with comorbidity 36/168, smoking history never/ever 37/149; 86.3 % LCP had stage IIIB and IV disease. In 43.2 % of LCP with negative or not performed fibrobronchoscopy (FBS), pathological diagnosis was obtained by other methods including surgical. Before treatment, patients obtained morphological verification of lung cancer—98.5 % histologically versus 1.5 % cytologically. The prevalent histo-type found was adenocarcionoma. In all, 88.7 % of LCP received systemic medical treatment while 11.3 %—palliative care. Only 2.5 % received adjuvant and 2.0 % neoadjuvant chemotherapy, while 84.2 % received medical therapy for advanced disease. In the last group, prognostic value for survival according to Cox-regression model reached ECOG performance status (PS) (HR 0.4; CI 0.23–0.63; p < 0.0001); weight loss (WL) prior to diagnosis (HR 2.03; CI 1.22–3.37; p < 0.01); number of treatment lines (HR 1.65; CI 1.2–2.67; p < 0.05); and platelet to lymphocyte ratio (PLR) (HR 0.48;CI 0.24–0.95; p < 0.001).

Conclusions

Lung cancer diagnosis and treatment in Bulgaria are managed according to the European guidelines. ECOG PS and WL are known prognostic factors in advanced LCP. Our results support prognostic impact of PLR on survival. However, the confirmation of this finding needs further prospective validation. The fact that the number of treatment lines impacts survival point out the importance of “continuum of care” concept in advanced LCP, treated with medical therapy.
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. PubMedCrossRef Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. PubMedCrossRef
2.
Zurück zum Zitat Malvezzi M, Bertuccio P, Levi F, et al. European cancer mortality predictions for the year 2012. Ann Oncol. 2012;23:1044–52. PubMedCrossRef Malvezzi M, Bertuccio P, Levi F, et al. European cancer mortality predictions for the year 2012. Ann Oncol. 2012;23:1044–52. PubMedCrossRef
3.
Zurück zum Zitat Cancer Incidence in Bulgaria 2010- National Cancer Registry, 2012: Vol.XX1;pp 18-20: Publisher Avia-24,Ltd. Cancer Incidence in Bulgaria 2010- National Cancer Registry, 2012: Vol.XX1;pp 18-20: Publisher Avia-24,Ltd.
4.
Zurück zum Zitat M. Reck, S. Popat, N. Reinmuth, et al., on behalf of the ESMO Guidelines Working Group. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;00:1–13. M. Reck, S. Popat, N. Reinmuth, et al., on behalf of the ESMO Guidelines Working Group. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;00:1–13.
5.
Zurück zum Zitat Hotta K, Fujiwara Y, Kiura K, et al. Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials. J Thoracic Oncol. 2007;2:402–7. CrossRef Hotta K, Fujiwara Y, Kiura K, et al. Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials. J Thoracic Oncol. 2007;2:402–7. CrossRef
6.
Zurück zum Zitat Brundage MD, Davies D, Mackillop WJ Prognostic factors in non-small cell lung cancer: adecade of progress. Chest 2002;122:1037–57. PubMedCrossRef Brundage MD, Davies D, Mackillop WJ Prognostic factors in non-small cell lung cancer: adecade of progress. Chest 2002;122:1037–57. PubMedCrossRef
7.
Zurück zum Zitat Kulesza P, Ramchandran K, Patel JD Emerging concepts in the pathology and molecular biology of advanced non-small cell lung cancer. Am J Clin Pathol. 2011;136: 228–38. PubMedCrossRef Kulesza P, Ramchandran K, Patel JD Emerging concepts in the pathology and molecular biology of advanced non-small cell lung cancer. Am J Clin Pathol. 2011;136: 228–38. PubMedCrossRef
8.
Zurück zum Zitat Ulas A, Turkoz FP, Silay K, et al. A laboratory prognostic index for patients with advanced non-small cell lung cancer. Plos One. 2014;9(12):e114471. doi:10.1371/journal.pone.0114471. PubMedCentralPubMedCrossRef Ulas A, Turkoz FP, Silay K, et al. A laboratory prognostic index for patients with advanced non-small cell lung cancer. Plos One. 2014;9(12):e114471. doi:10.1371/journal.pone.0114471. PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Kasymjanova G, MacDonald N, Agulnik JS, et al. The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer. Curr Oncol. 2010;17(4):52–58. PubMedCentralPubMedCrossRef Kasymjanova G, MacDonald N, Agulnik JS, et al. The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer. Curr Oncol. 2010;17(4):52–58. PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Trape J, Montesinos J, Catot S, Buxo J, Franquesa J, et al. A prognostic score based on clinical factors and biomarkers for advanced non-small cell lung cancer. Int J Biol Markers. 2012;27(3):257–62. CrossRef Trape J, Montesinos J, Catot S, Buxo J, Franquesa J, et al. A prognostic score based on clinical factors and biomarkers for advanced non-small cell lung cancer. Int J Biol Markers. 2012;27(3):257–62. CrossRef
11.
Zurück zum Zitat Jafri SH, Shi R, Mills G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer. 2013;13:158–67. PubMedCentralPubMedCrossRef Jafri SH, Shi R, Mills G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer. 2013;13:158–67. PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC, editor. AJCC Cancer Staging Handbook. 7th ed. New York: Springer, 2010 Edge SB, Byrd DR, Compton CC, editor. AJCC Cancer Staging Handbook. 7th ed. New York: Springer, 2010
13.
Zurück zum Zitat Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:706–14. PubMedCrossRef Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:706–14. PubMedCrossRef
14.
Zurück zum Zitat Zhang Y, Kang S, Fang W, et al. Impact of smoking status on EGFR-TKI efficacy for advanced non-small-cell lung cancer in EGFR mutants: a meta-analysis. Clin Lung Cancer. 2014. doi:10.1016/j.cllc.2014.09.008. (pii: S1525–7304(14)00196–X) Zhang Y, Kang S, Fang W, et al. Impact of smoking status on EGFR-TKI efficacy for advanced non-small-cell lung cancer in EGFR mutants: a meta-analysis. Clin Lung Cancer. 2014. doi:10.1016/j.cllc.2014.09.008. (pii: S1525–7304(14)00196–X)
15.
Zurück zum Zitat O’Malley M, King AN, Conte M, et al. Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer. J Thorac Oncol. 2014;9(7):917–26. doi:10.1097/JTO.0000000000000191. PubMedCrossRef O’Malley M, King AN, Conte M, et al. Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer. J Thorac Oncol. 2014;9(7):917–26. doi:10.1097/JTO.0000000000000191. PubMedCrossRef
17.
Zurück zum Zitat Biswas M, Ades AE, Hamilton W. Symptom lead times in lung and colorectal cancers: what are the benefits of symptom-based approaches to early diagnosis? Br J Cancer. 2015;112(2):271–7. doi:10.1038/bjc.2014.597. PubMedCrossRef Biswas M, Ades AE, Hamilton W. Symptom lead times in lung and colorectal cancers: what are the benefits of symptom-based approaches to early diagnosis? Br J Cancer. 2015;112(2):271–7. doi:10.1038/bjc.2014.597. PubMedCrossRef
19.
Zurück zum Zitat Goldberg RM, Rothenberg ML, Van Cutsem E, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist. 2007;12(1):38–50. PubMedCrossRef Goldberg RM, Rothenberg ML, Van Cutsem E, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist. 2007;12(1):38–50. PubMedCrossRef
20.
Zurück zum Zitat McMilan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009:12(3):223–6 CrossRef McMilan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009:12(3):223–6 CrossRef
21.
Zurück zum Zitat Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00–03. Eur J Cancer. 2009;5:1950–8. CrossRef Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00–03. Eur J Cancer. 2009;5:1950–8. CrossRef
22.
Zurück zum Zitat Qiu M, Zhou Y, Jin Y, et al. Prognostic effect of high pretreatment neutrophil to lymphocyte ratio on survival of patients with gastric adenocarcinoma in China. Int J Bio Markers. 2014;30:e96–103. doi:10.5301/jbm.5000123. Qiu M, Zhou Y, Jin Y, et al. Prognostic effect of high pretreatment neutrophil to lymphocyte ratio on survival of patients with gastric adenocarcinoma in China. Int J Bio Markers. 2014;30:e96–103. doi:10.5301/jbm.5000123.
23.
Zurück zum Zitat Supoken A, Kleebkaow P, Chumworathayi B, et al. Elevated preoperative platelet to lymphocyte ratio associated with decreased survival of women with ovarian clear cell carcinoma. Asian Pac J Cancer Prev. 2014;15(24):10831–6. PubMedCrossRef Supoken A, Kleebkaow P, Chumworathayi B, et al. Elevated preoperative platelet to lymphocyte ratio associated with decreased survival of women with ovarian clear cell carcinoma. Asian Pac J Cancer Prev. 2014;15(24):10831–6. PubMedCrossRef
24.
Zurück zum Zitat Kusumanto Y, Dam W, Hospers G, et al. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 2003;6:283–7 PubMedCrossRef Kusumanto Y, Dam W, Hospers G, et al. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 2003;6:283–7 PubMedCrossRef
Metadaten
Titel
Lung cancer in Bulgaria ‒ diagnosis, treatment, and factors affecting survival
Bulgarian Single Institution experience in lung cancer treatment
verfasst von
MD, PhD Zhasmina Mihaylova
MD Vera Megdanova
MD Veneta Petrova
MD Dobromira Petkova
MD Albena Fakirova
MD, PhD Mihaela Petrova
MD, PhD Rumen Asenov
MD Iva Kisjova
MD, PhD Milena Encheva
MD Hristo Dinev
Publikationsdatum
01.06.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-015-0214-8